# Emails with Arif Jetha for determining scope of work for Radiant Project
From: Will Paton <will@prolific-machines.com>
Reply-To: will@prolific-machines.com
To:   Arif Jetha <ajetha@radiantbio.com>
Cc:   Xinwen He <xinwenhe@radiantbio.com>, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Vidar van der Meijden <vidar@prolific-machines.com>
Date: Monday, December 1 2025 at 6:17 PM PST

Subject: Radiant <> Prolific Proposed Statement of Work

Hi Arif,
I‚Äôve attached the proposed SOW for your review. We‚Äôve included a few comments in areas where your input is needed, as well as questions highlighted in yellow. Please review the document, add any suggested changes or additions, and feel free to reach out if anything needs clarification.
Thanks,
Will
[1]

--
[1] https://lh7-us.googleusercontent.com/docsz/AD_4nXexdNuyilZiIfH3t8Qx21Z57gTNnZvHeA_01nkbTWYJmUv_OQ13BjCwxRK8AkDiqcjb1z75A5Cfoh0E1Eb5H1Tpp9_tQloMLhwDJRRAoK3huktkpNEU2Md5RwTx91gBZvd_IGViQoh5wkdbeQoN5DPcVkB1?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Arif Jetha <ajetha@radiantbio.com>
To:   will@prolific-machines.com
Cc:   Xinwen He <xinwenhe@radiantbio.com>, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Vidar van der Meijden <vidar@prolific-machines.com>
Date: Wednesday, December 3 2025 at 12:54 PM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Hi Will,
Thanks for your patience as we reviewed the SOW. I have attached here a copy with some comments and suggested edits.
I saw your other email but it looked like most of the questions you asked were included in the SOW and so hopefully this addresses these points, but happy to discuss further on Friday during the call.
Looking forward to connecting then.

------

From: Will Paton <will@prolific-machines.com>
Reply-To: will@prolific-machines.com
To:   Shahram Misaghi <shahram.misaghi@prolific-machines.com>
Cc:   Amritha Menon <amritha.menon@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>
Date: Wednesday, December 3 2025 at 4:29 PM PST

Subject: Fwd: RE: Radiant <> Prolific Proposed Statement of Work

Hi team,
Arif from Radiant has responded to the proposed SOW we shared and included some comments for us to review. Could you take a look and share your feedback in reply to this message?
I‚Äôd like to discuss the key points during our meeting with them on Friday. Thanks!
[1]

--
[1] https://lh7-us.googleusercontent.com/docsz/AD_4nXexdNuyilZiIfH3t8Qx21Z57gTNnZvHeA_01nkbTWYJmUv_OQ13BjCwxRK8AkDiqcjb1z75A5Cfoh0E1Eb5H1Tpp9_tQloMLhwDJRRAoK3huktkpNEU2Md5RwTx91gBZvd_IGViQoh5wkdbeQoN5DPcVkB1?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Will Paton <will@prolific-machines.com>
Reply-To: will@prolific-machines.com
To:   Will Paton <will@prolific-machines.com>
Cc:   Shahram Misaghi <shahram.misaghi@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>
Date: Thursday, December 4 2025 at 8:53 AM PST

Subject: Re: Fwd: RE: Radiant <> Prolific Proposed Statement of Work

Shahram made a good point ‚Äì it will be easier for us to collaborate in a Google Doc. Here is the doc [1] with Arif's comments ‚Äì please leave your comments directly there.
Thanks!
[2]

--
[1] https://docs.google.com/document/d/1KGq8OxK_ruRU-Gf24Vm6QOhOCFDgk7iq/edit
[2] https://lh7-us.googleusercontent.com/docsz/AD_4nXexdNuyilZiIfH3t8Qx21Z57gTNnZvHeA_01nkbTWYJmUv_OQ13BjCwxRK8AkDiqcjb1z75A5Cfoh0E1Eb5H1Tpp9_tQloMLhwDJRRAoK3huktkpNEU2Md5RwTx91gBZvd_IGViQoh5wkdbeQoN5DPcVkB1?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Shahram Misaghi <shahram.misaghi@prolific-machines.com>
To:   will@prolific-machines.com
Cc:   Amritha Menon <amritha.menon@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>
Date: Thursday, December 4 2025 at 9:04 AM PST

Subject: Re: Fwd: RE: Radiant <> Prolific Proposed Statement of Work

Thanks Will¬†üôè
[1]

--
[1] https://lh7-rt.googleusercontent.com/docsz/AD_4nXeSyrzGtlKZgQEbKiy5u6sqYBcgBDva-tOd-fW3z8eOF-JfV-PDZ2uDGf5nAvZdnPEAtIqUoMkjXndJJCX3-dmy2jv1qg_PgVD7oPp77QLirNeAPEBGQfayTS1-ewE0WvR00mmIEO5yv7ri-YwFCYN-4UtD?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Will Paton <will@prolific-machines.com>
Reply-To: will@prolific-machines.com
To:   Arif Jetha <ajetha@radiantbio.com>
Cc:   Xinwen He <xinwenhe@radiantbio.com>, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Vidar van der Meijden <vidar@prolific-machines.com>
Date: Friday, December 5 2025 at 10:23 PM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Arif and Xinwen,
Thank you for the meeting today¬†‚Äì we¬†¬†appreciate you taking the time to address all our questions. I‚Äôve updated the attached SOW (rev 3) to reflect the suggestions and decisions discussed during the meeting. Please review it and let us know if there are any additional changes you'd like to see.
We'll await your update regarding the molecule selections following your meeting with Jacqueline on 12/17. In the meantime, please let us know if you receive any further information on whether the terms of your license with Thermo permit you to share the DNA sequences with us directly.
Best,
Will
[1]

--
[1] https://lh7-us.googleusercontent.com/docsz/AD_4nXexdNuyilZiIfH3t8Qx21Z57gTNnZvHeA_01nkbTWYJmUv_OQ13BjCwxRK8AkDiqcjb1z75A5Cfoh0E1Eb5H1Tpp9_tQloMLhwDJRRAoK3huktkpNEU2Md5RwTx91gBZvd_IGViQoh5wkdbeQoN5DPcVkB1?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Arif Jetha <ajetha@radiantbio.com>
To:   will@prolific-machines.com
Cc:   Xinwen He <xinwenhe@radiantbio.com>, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Vidar van der Meijden <vidar@prolific-machines.com>
Date: Tuesday, December 9 2025 at 6:21 PM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Hi Will,
Thanks for revising and sending. I‚Äôve attached here some additional comments ‚Äì hope this clarifies things. Please let me know if there are any additional questions.
Thanks,

------

From: Will Paton <will@prolific-machines.com>
Reply-To: will@prolific-machines.com
To:   Arif Jetha <ajetha@radiantbio.com>
Cc:   Xinwen He <xinwenhe@radiantbio.com>, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Shahram Misaghi <shahram.misaghi@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Wednesday, December 10 2025 at 5:48 PM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Hi Arif,
Thanks for the comments on the SOW and for clarifying the vector-table nomenclature and potential clone-screening work. After an internal discussion today focused on how we demonstrate titer improvements, we realized the current SOW structure may not give the clearest comparison for evaluating the optogenetic system.
One of our shared goals is to show directional titer improvement for the HIV Multabodies, benchmarked against constitutive expression, so Radiant can directly assess the added value of optogenetic control relative to your current¬†approach.
Right now, the SOW (1) uses only two-vector designs and (2) relies on seed-train illumination as a CMV mimic, without a true CMV control. Our concern is that this may understate the benefit of optogenetic control at the pool stage.
**Proposed adjustment**
To get a cleaner constitutive comparison, we‚Äôd like to propose the following change:
*   Replace Pools 5 and 6 with single-vector designs, one driven by CMV and one by the optogenetic promoter.
*   This would give us a straightforward ‚ÄúCMV vs. opto‚Äù comparison at the pool stage, while keeping the rest of the two-vector design space intact.
We believe this will provide a more interpretable readout of incremental titer benefit relative to a realistic CMV baseline.
**Seed-train illumination (‚Äúmock CMV‚Äù) control**
If you feel a CMV-mimicking seed-train illumination arm is still important, we‚Äôre open to including it with a narrower scope:
*   Run the seed-train illumination control only for our top 2‚Äì3 pools in a second round of production runs, rather than for all 10 pools.
*   For those priority pools, we would illuminate during the final 2‚Äì3 seed-train passages before the production run, where expression and growth/productivity trade-offs are more meaningful.
**Next steps**
Could we schedule a short call (20‚Äì30 minutes) to align on the comparison strategy that will give Radiant the most decision-useful proof-of-concept readout on titer improvement?
Here are some windows that work on our side:
\- Fri Dec 12: 3:30‚Äì4:00 pm, 5:30‚Äì6:00 pm
\- Mon Dec 15: 2:45‚Äì4:15 pm
\- Tue Dec 16: 1:15‚Äì1:45 pm, 3:30‚Äì4:00 pm, 5:45‚Äì7:00 pm
\- Wed Dec 17: 4:45‚Äì5:30 pm, 6:00‚Äì7:00 pm
\- Dec 18: 11:00 am‚Äì1:00 pm, 5:00‚Äì7:00 pm
If this general direction sounds reasonable, please let us know what works best for you, or feel free to suggest an alternative comparison that you think would be more informative.
Thanks,
Will
[1]

--
[1] https://lh7-us.googleusercontent.com/docsz/AD_4nXexdNuyilZiIfH3t8Qx21Z57gTNnZvHeA_01nkbTWYJmUv_OQ13BjCwxRK8AkDiqcjb1z75A5Cfoh0E1Eb5H1Tpp9_tQloMLhwDJRRAoK3huktkpNEU2Md5RwTx91gBZvd_IGViQoh5wkdbeQoN5DPcVkB1?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Arif Jetha <ajetha@radiantbio.com>
To:   will@prolific-machines.com
Cc:   Xinwen He <xinwenhe@radiantbio.com>, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Shahram Misaghi <shahram.misaghi@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Thursday, December 11 2025 at 3:32 AM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Hi Will,
Thanks for sending. I think this will work but would be good to jump on a quick call to clarify and finalize. Happy to discuss further.
I wasn‚Äôt sure if the times you mentioned were in ET or PT but I‚Äôm free on Monday at 345-415 ET or Tuesday at 115 PT / 415 ET.
Thanks,

------

From: Will Paton <will@prolific-machines.com>
Reply-To: will@prolific-machines.com
To:   Arif Jetha <ajetha@radiantbio.com>
Cc:   Xinwen He <xinwenhe@radiantbio.com>, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Shahram Misaghi <shahram.misaghi@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Thursday, December 11 2025 at 10:00 AM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Hi Arif,
Great. I just sent an invite for Monday¬†at 3:45‚Äì4:15 pm ET. Whoops - I must have removed the time zone from my email!
Looking forward to chatting on Monday.
Will
[1]

--
[1] https://lh7-us.googleusercontent.com/docsz/AD_4nXexdNuyilZiIfH3t8Qx21Z57gTNnZvHeA_01nkbTWYJmUv_OQ13BjCwxRK8AkDiqcjb1z75A5Cfoh0E1Eb5H1Tpp9_tQloMLhwDJRRAoK3huktkpNEU2Md5RwTx91gBZvd_IGViQoh5wkdbeQoN5DPcVkB1?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Arif Jetha <ajetha@radiantbio.com>
To:   will@prolific-machines.com
Cc:   Xinwen He <xinwenhe@radiantbio.com>, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Shahram Misaghi <shahram.misaghi@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Thursday, December 11 2025 at 11:02 AM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Sounds great, thank you!

------

From: Will Paton <will@prolific-machines.com>
Reply-To: will@prolific-machines.com
To:   Arif Jetha <ajetha@radiantbio.com>
Cc:   Xinwen He <xinwenhe@radiantbio.com>, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Shahram Misaghi <shahram.misaghi@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Wednesday, December 17 2025 at 3:32 PM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Hi Arif,
I hope your call with Jacqueline went well¬†today! Thank you again for taking the time to meet with us on Monday to align on the strategy for incorporating a CMV comparison into our designs. I've attached the latest version (Rev 004) of the SOW to this email. I‚Äôve included some rationale for the various pools to ensure our shared understanding is reflected in the document.
Following the meeting, Amritha had a question: would you be able to share one of your CMV pools with us to use as a control for our process? A CMV pool for the RSV Multabody would be ideal, but an HIV Multabody pool would also suffice.
Thanks,
Will
[1]

--
[1] https://lh7-us.googleusercontent.com/docsz/AD_4nXexdNuyilZiIfH3t8Qx21Z57gTNnZvHeA_01nkbTWYJmUv_OQ13BjCwxRK8AkDiqcjb1z75A5Cfoh0E1Eb5H1Tpp9_tQloMLhwDJRRAoK3huktkpNEU2Md5RwTx91gBZvd_IGViQoh5wkdbeQoN5DPcVkB1?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Arif Jetha <ajetha@radiantbio.com>
To:   will@prolific-machines.com
Cc:   Xinwen He <xinwenhe@radiantbio.com>, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Shahram Misaghi <shahram.misaghi@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Friday, December 19 2025 at 6:24 AM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Hi Will,
Thanks for sending. I think we are almost there, see attached for some additional comments for the SOW.
Regarding the CMV pools question below, are you referring to a frozen aliquot of the cells used in transfection?
Sara, I also wanted to check on the status of the service agreement now that the terms have been agreed to. When do you anticipate that being finalized?
Thanks!

------

From: Sara Kemppainen <sara.kemppainen@prolific-machines.com>
To:   Arif Jetha <ajetha@radiantbio.com>
Cc:   will@prolific-machines.com, Xinwen He <xinwenhe@radiantbio.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Shahram Misaghi <shahram.misaghi@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Friday, December 19 2025 at 9:20 AM PST

Subject: Re: Radiant <> Prolific Proposed Statement of Work

Hi Arif,
Thanks so much for this! I‚Äôll let Will take a look and comment on the SOW.
I have the service agreement with our lawyers now and made a few updates yesterday to the first version. I‚Äôm expecting to share it with you by EOD today.
We‚Äôre still waiting on **Deb‚Äôs signature on the key terms.**¬†Would you mind giving her a quick ping on your end? We‚Äôre so close üòä
All the best,
Sara
[1]

--
[1] https://lh7-us.googleusercontent.com/docsz/AD_4nXe4gUf5MVSX38Ws3zYhv-mXTNnEFwIyYewGPc7NOkcR_lmq-GQmjIYQfCRxOG6CTmLHsqtZsOG64nrAN7wCWMPh5sdsfuPM1F8ekFhgvBoquojl6efx2aQC1C6uDD8MgA5HV_iePfT17V32oy3jFETj94I?key=dLnGNvqLdAPKMK_avuC22Q

------

From: Will Paton <will@prolific-machines.com>
Reply-To: will@prolific-machines.com
To:   Sara Kemppainen <sara.kemppainen@prolific-machines.com>
Cc:   Arif Jetha <ajetha@radiantbio.com>, Xinwen He <xinwenhe@radiantbio.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Shahram Misaghi <shahram.misaghi@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Friday, December 19 2025 at 3:31 PM PST

Subject: Re: Radiant <> Prolific Proposed Statement of Work

Hi Arif,
Thanks for flagging the issue with our vector designs for the monospecific MBs. We‚Äôve updated the design to reflect the intended 2:1:1 ratio for FabAHferr : FabANferr : FcCferr in the monospecifics, incorporating four genes (including two copies of FabAHferr) to achieve this balance. The revised vector designs are attached in the Word document.
As for the CMV pools, we were wondering if it would be possible to obtain a frozen aliquot of a stable cell pool expressing one of the molecules I mentioned in my last email (RSV MB or HIV MB). While it‚Äôs not essential, it would serve as a useful control for comparison. Let me know if this can be arranged.
Thanks!
Will
[1]

--
[1] https://lh7-us.googleusercontent.com/docsz/AD_4nXexdNuyilZiIfH3t8Qx21Z57gTNnZvHeA_01nkbTWYJmUv_OQ13BjCwxRK8AkDiqcjb1z75A5Cfoh0E1Eb5H1Tpp9_tQloMLhwDJRRAoK3huktkpNEU2Md5RwTx91gBZvd_IGViQoh5wkdbeQoN5DPcVkB1?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Shahram Misaghi <shahram.misaghi@prolific-machines.com>
To:   will@prolific-machines.com
Cc:   Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Arif Jetha <ajetha@radiantbio.com>, Xinwen He <xinwenhe@radiantbio.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Sunday, December 21 2025 at 12:13 PM PST

Subject: Re: Radiant <> Prolific Proposed Statement of Work

Thanks Will and Arif,
@Arif,
Yes, the plan is to have a CMV stable cell line that expresses one of your Multabodies as a control in our hands to ensure that we can more or less replicate what you get.
Also, Thanks for your pointer on the vector design
@will and¬†@Arif,It will be very helpful to have a meeting to go over all the vector designs to ensure that we are all aligned before starting to clone.
Best,
Shahram
[1]

--
[1] https://lh7-rt.googleusercontent.com/docsz/AD_4nXeSyrzGtlKZgQEbKiy5u6sqYBcgBDva-tOd-fW3z8eOF-JfV-PDZ2uDGf5nAvZdnPEAtIqUoMkjXndJJCX3-dmy2jv1qg_PgVD7oPp77QLirNeAPEBGQfayTS1-ewE0WvR00mmIEO5yv7ri-YwFCYN-4UtD?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Shahram Misaghi <shahram.misaghi@prolific-machines.com>
To:   will@prolific-machines.com
Cc:   Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Arif Jetha <ajetha@radiantbio.com>, Xinwen He <xinwenhe@radiantbio.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Sunday, December 21 2025 at 6:25 PM PST

Subject: Re: Radiant <> Prolific Proposed Statement of Work

Hi Arif,
Just following up on my previous email. I would like to understand the strategy for multibodies a bit better.
If we have a ratio of 16:8:4:4 for Fab-HFerr:Fab-NFerr:Fab-CFerr:Fc-CFerr for a Multabody, that means that for a 32 available¬†positions, we will have a total of **28 parts Fabs and 4 parts Fc** in Multabodies. I do understand that for Trispecific Multabodies we will have 16 of Fab1, 8 of Fab2, and 4 of Fab3¬†+ 4 Fc moieties. but if for the monospecific we use: HighOpto-Fab1BHferr-HighOpto-Fab1BHferr-HighOpto-FabB1Nferr-HighOpto -FcCferr **without** using a Fab1Cferr, the ratios will become **24 parts Fabs and 8 Parts Fc** in the Multabodies.
Are we good with that ratio? Will having more Fc moieties impact the function of Multabodies?
Best,
Shahram
[1]

--
[1] https://lh7-rt.googleusercontent.com/docsz/AD_4nXeSyrzGtlKZgQEbKiy5u6sqYBcgBDva-tOd-fW3z8eOF-JfV-PDZ2uDGf5nAvZdnPEAtIqUoMkjXndJJCX3-dmy2jv1qg_PgVD7oPp77QLirNeAPEBGQfayTS1-ewE0WvR00mmIEO5yv7ri-YwFCYN-4UtD?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Arif Jetha <ajetha@radiantbio.com>
To:   Sara Kemppainen <sara.kemppainen@prolific-machines.com>
Cc:   will@prolific-machines.com, Xinwen He <xinwenhe@radiantbio.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Shahram Misaghi <shahram.misaghi@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Monday, December 22 2025 at 8:49 AM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Thanks, Sara. I just spoke with Deb and she let me know that she signed the key terms doc. Can you confirm receipt?
In parallel, our legal is reviewing the service agreement doc that you had sent, I will keep you posted on any comments we receive.
Shahram / Will, I saw your other emails and will respond later today.
Thanks,
[1]

--
[1] https://d5nYcf04.na2.hs-sales-engage.com/Cto/JA+23284/d5nYcf04/R5R8b42f4N8DR4g12fJzpW1ZlGp93LGTtwW1X1nNV1X1QJrW1GzKDc1Q1GRqW1_jT_f24T1GyW23h3kx1Z0m5Pn1X0-hs4W1

------

From: Arif Jetha <ajetha@radiantbio.com>
To:   Shahram Misaghi <shahram.misaghi@prolific-machines.com>, will@prolific-machines.com
Cc:   Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Xinwen He <xinwenhe@radiantbio.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Tuesday, December 23 2025 at 6:14 AM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Hi Shahram, Will,
Will, thanks for clarifying the points in the SOW, everything is clear from my side.
Shahram, it‚Äôs a very good point. The gist is that yes, there may be a discrepancy between the Fab # in mono and trispecifics. The reality is that we know that a monospecific MB won‚Äôt be a lead candidate and so it acts as a comparison for how expression may change when we increase complexity (going from mono to tri-specific).
Most of our neutralization data is with trispecifics consisting of 28 Fabs. We have one experiment where we tested a trispecific using 24 Fabs (mimicking the monospecific design) and we had a small but significant reduction in viral neutralization activity. Its clear to us that 28 Fabs in a trispecific design are preferable for activity which is why we recommend this design. If possible, by keeping the same stable pool plan and only using the optogenetics, it might be worth exploring the 24 Fab combination in parallel to the 28-Fab combination. If not, I still think this is the best plan forward.
I hope that clarifies things but please let me know if there are any additional questions.
Thanks,
Arif

------

From: Shahram Misaghi <shahram.misaghi@prolific-machines.com>
To:   Arif Jetha <ajetha@radiantbio.com>
Cc:   will@prolific-machines.com, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Xinwen He <xinwenhe@radiantbio.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Tuesday, December 23 2025 at 3:48 PM PST

Subject: Re: Radiant <> Prolific Proposed Statement of Work

Thanks for explaining¬†Arif,
Yes, that clarifies almost all my questions. Once the sequences are decided and finalized, let's go over the vector designs one last time before we start cloning (just in case!).
The 2 vector pools may result in some pools (or more likely clones) with 24 vs. 28 Fabs when using different light intensities, but we likely need different vector designs to achieve that more precisely.
Best,
Shahram
[1]

--
[1] https://lh7-rt.googleusercontent.com/docsz/AD_4nXeSyrzGtlKZgQEbKiy5u6sqYBcgBDva-tOd-fW3z8eOF-JfV-PDZ2uDGf5nAvZdnPEAtIqUoMkjXndJJCX3-dmy2jv1qg_PgVD7oPp77QLirNeAPEBGQfayTS1-ewE0WvR00mmIEO5yv7ri-YwFCYN-4UtD?key=_A2fLf6Rz3cFz4nDnv03sg

------

From: Arif Jetha <ajetha@radiantbio.com>
To:   Shahram Misaghi <shahram.misaghi@prolific-machines.com>
Cc:   will@prolific-machines.com, Sara Kemppainen <sara.kemppainen@prolific-machines.com>, Xinwen He <xinwenhe@radiantbio.com>, Vidar van der Meijden <vidar@prolific-machines.com>, Noreen Wauford <noreen.wauford@prolific-machines.com>, Amritha Menon <amritha.menon@prolific-machines.com>
Date: Wednesday, December 24 2025 at 5:14 AM PST

Subject: RE: Radiant <> Prolific Proposed Statement of Work

Sounds good. Wishing you all an enjoyable Holiday break!
Arif